GHRP-2 and CJC-1295 No DAC Stack: What the Research Shows

Why GHRP-2 and CJC-1295 No DAC Are Studied Together

Research has examined GHRP-2 and GHRH together under several experimental conditions. This provides relevant background for examining a combination involving GHRP-2 and a GHRH-related peptide.

However, those findings relate specifically to the compounds and conditions tested in each experiment.

Research on GHRP-2 and GHRH Combinations

A 1995 randomized study compared GHRH1-29NH2, GHRP-2, and their combination in eight healthy men. The combination produced a higher GH area under the curve than either treatment alone. However, the combined response was not significantly different from the sum of the two individual responses. The researchers therefore did not demonstrate synergy in that experiment.

A 1996 study examined chronic GHRP-2, GHRH, and their combination over 7 to 30 days in younger and older adults. Under those conditions, chronic administration of either GHRP-2 or GHRH converted an additive combined response into a synergistic response.

Further research found that the interaction could vary with participant characteristics and experimental conditions. In a 2004 study of older adults, acute GHRP-2/GHRH synergy differed between younger and older participants and between women and men. The study also found that combined 24-hour administration produced greater GH secretion than either stimulus alone under specified conditions.

A 2009 study involving 47 men examined factors associated with GHRH and GHRP-2 synergy. Age and abdominal visceral fat were negatively associated with the measured synergy, while IGF-I and IGFBP-3 were positively associated with it.

The research therefore does not show one uniform GHRP-2/GHRH response. Findings varied by experimental design and study population characteristics.

Research on the GHRP-2 and CJC-1295 No DAC Combination

Published research does not directly evaluate GHRP-2 in combination with CJC-1295 No DAC.

The distinction between CJC-1295 forms is important. The 2005 study characterized CJC-1295 as a tetrasubstituted hGRF(1-29) analog with a modification that enables binding to serum albumin and extends its circulation.

A subsequent randomized study evaluated this long-acting CJC-1295 in healthy adults and measured its pharmacokinetic profile together with GH and IGF-I responses. GHRP-2 was not included in the experimental design.

Another human study examined GH pulsatility following CJC-1295 administration and likewise evaluated CJC-1295 independently rather than in combination with GHRP-2.

These studies provide evidence for the separately studied long-acting CJC-1295 form. They do not establish findings for GHRP-2 combined with CJC-1295 No DAC.

What the Available Research Shows

The GHRP-2/GHRH literature shows that combined responses have been observed under several experimental conditions, but the magnitude and character of those responses were not consistent across studies.

That evidence should remain separate from the CJC-1295 literature. The published CJC-1295 studies evaluated the long-acting form and did not directly test the GHRP-2 and CJC-1295 No DAC combination.

Current Research Perspective

The available literature establishes research on GHRP-2 and GHRH combinations and separate research on CJC-1295. It does not establish direct experimental findings for GHRP-2 combined with CJC-1295 No DAC.

The specific combination therefore remains distinct from the related GHRP-2/GHRH studies and the published long-acting CJC-1295 research.

FAQs

References

1. Tiulpakov AN, Brook CG, Pringle PJ, Peterkova VA, Volevodz NN, Bowers CY. GH responses to intravenous bolus infusions of GH releasing hormone and GH releasing peptide 2 separately and in combination in adult volunteers. Clin Endocrinol (Oxf). 1995 Sep;43(3):347-50. PubMed ↗
2. Bowers CY, Granda-Ayala R. GHRP-2, GHRH and SRIF interrelationships during chronic administration of GHRP-2 to humans. J Pediatr Endocrinol Metab. 1996 Jun;9 Suppl 3:261-70. PubMed ↗
3. Bowers CY, Granda R, Mohan S, Kuipers J, Baylink D, Veldhuis JD. Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women. J Clin Endocrinol Metab. 2004 May;89(5):2290-300. PubMed ↗
4. Veldhuis JD, Bowers CY. Determinants of GH-releasing hormone and GH-releasing peptide synergy in men. Am J Physiol Endocrinol Metab. 2009 May;296(5):E1085-92. PubMed ↗
5. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006 Mar;91(3):799-805. PubMed ↗
6. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006 Dec;91(12):4792-7. PubMed ↗